Results 231 to 240 of about 7,007,196 (291)

Cannabinoid CB1 allosteric ligands suppress inflammatory pain in male mice without tolerance, motor impairment, memory deficits or respiratory depression

British Journal of Pharmacology, Volume 183, Issue 20, Page 6132-6153, October 2026.
Abstract Background and Purpose Positive allosteric modulators (PAMs) engage sites distinct from the orthosteric CB1 cannabinoid receptor binding site. GAT211, a racemic ligand, contains GAT228 (R) and GAT229 (S) enantiomers. Whether enantiomer‐mediated differences in allosteric activation or positive allosteric modulation translate into differences in
Ifeoluwa D. Solomon, Sumanta Garai, Ganesh A. Thakur, Andrea G. Hohmann   +3 more
wiley   +1 more source

Examining Differences Among Opioid Agonist Treatment Clients in Regional and Metropolitan Settings of New South Wales, Australia. [PDF]

Aust J Rural Health
Winter DT, Monds LA, Lintzeris N, Haber PS, Day CA.   +4 more
europepmc   +1 more source

Novel Histopathologic Features of Diffuse Blue‐Gray Hyperpigmentation Associated With Kratom Use: A Case Report and Literature Review

Journal of Cutaneous Pathology, Volume 53, Issue 10, Page 887-892, October 2026.
ABSTRACT Background Drug‐induced hyperpigmentation accounts for 10%–20% of acquired pigmentary disorders and can be misdiagnosed for other causes such as melasma, post inflammatory changes, or heavy metal deposition. Kratom (Mitragyna speciosa), a Southeast Asian plant with an opioid‐like profile, has been increasingly used in the United States for ...
Rita Kamoua, Kristen Paradine, Craig A. Rohan, Mary McDaniel, Diane Perkins   +4 more
wiley   +1 more source

Psychiatrist-led hepatitis C (HCV) treatment at an opioid agonist treatment clinic in Stockholm- a model to enhance the HCV continuum of care. [PDF]

BMC Psychiatry
Klasa PE, Sandell M, Aleman S, Kåberg M.   +3 more
europepmc   +1 more source

Cochrane in CORR® : Opioid Agonist Treatment for People Who are Dependent on Pharmaceutical Opioids. [PDF]

Clin Orthop Relat Res
Madden K.
europepmc   +1 more source

The association between benzodiazepine co-prescription, opioid agonist treatment and mortality: a systematic review. [PDF]

BMC Psychiatry
Hestevik CH, Evensen LH, Kornør H, Skeie I.   +3 more
europepmc   +1 more source

Vaping to quit smoking: Qualitative study of people receiving opioid agonist treatment. [PDF]

Drug Alcohol Rev
Kypri K, Austin E, Jackson M, Wright K, Shui A, Li A, Sathasivam V, Bonevski B, Dunlop AJ.   +8 more
europepmc   +1 more source

Identifying key risk factors for intentional self-harm, including suicide, among a cohort of people prescribed opioid agonist treatment: A predictive modelling study. [PDF]

Addiction
Jones NR, Hickman M, Bharat C, Nielsen S, Larney S, Ghouse NF, Lappin J, Degenhardt L.   +7 more
europepmc   +1 more source

Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation. [PDF]

Pharmacoeconomics
Chaudhary P, Fadnes LT, Fosse S, Chalabianloo F, Johansson KA.   +4 more
europepmc   +1 more source

Abstracts from the 2026 Congress of the Scandinavian Society of Anesthesiology and Intensive Care Medicine, Reykjavik, Iceland, June 10–12, 2026

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 9, October 2026.
wiley   +1 more source